SC 13G/A: Biodexa Pharmaceuticals Plc

AI Summary

SC 13G/A filing by Biodexa Pharmaceuticals Plc.

Risk Assessment

Risk Level: low

Filing Documents

• ea0221977-13ga1brio_bio.htm (SC 13G/A) — 72KB
• 0001213900-24-100449.txt ( ) — 74KB

(a)

Item 1(a). Name of Issuer Biodexa Pharmaceuticals PLC (the “Issuer”)

(b)

Item 1(b). Address of the Issuer’s Principal Executive Offices 1 Caspian Point, Caspian Way Cardiff, CF10 4DQ, United Kingdom.

(a)

Item 2(a). Names of Persons Filing This Schedule 13G is filed jointly by: Brio Capital Master Fund Ltd. Brio Capital Management LLC The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.” Information with respect to each Reporting Person is given solely by such Reporting Person, and no Reporting Person assumes responsibility for the accuracy or completeness of the information furnished by another Reporting Person. Each Reporting Person expressly declares that neither the filing of this statement nor anything herein shall be construed as an admission that such Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

(b)

Item 2(b). Address of the Principal Business Office, or if none, Residence: c/o Brio Capital Management LLC, 100 Merrick Road, Suite 401 W. Rockville Center, NY 11570.

(c)

Item 2(c). Citizenship Brio Capital Master Fund Ltd. – Cayman Islands Brio Capital Management LLC – United

(d)

Item 2(d). Title of Class of Securities American Depository Shares. Each American Depository Share represents 400 ordinary shares, nominal value £0.001 per share, of the Issuer.

(e)

Item 2(e). CUSIP Number 59564R708 Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: ¨ (a) Broker or Dealer registered under Section 15 of the Exchange Act. ¨ (b) Bank as defined in Section 3(a)(b) or the Exchange Act. ¨ (c) Insurance company as defined in Section 3(a)(19) of the Exchange Act. ¨ (d) Investment company registered under Section 8 of the Investment Company Act. ¨ (e) An Investment adviser in accordance with Rule 13d-1 (b)(1)(ii)(e). ¨ (f) An employee benefit plan or endowment fund in accordance with Rule 13d 1(b)(1)(ii)(f). ¨ (g) A Parent Holding Company or control person in accordance with Rule 13d 1(b)(1)(ii)(g). ¨ (h) A Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act. ¨ (i) A Church Plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act. ¨ (j) Group, in accordance with Rule 13d-1 (b)(1)(ii)(j). Not applicable 4 Item 4. The information required by Items 4(a)-(c) is set forth in Rows 5-11 of each Cover Page and is incorporated herein by reference. Each Reporting Person expressly declares that neither the filing of this statement nor anything herein shall be construed as an admission that such Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement. Item 5. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: Item 6. Not Applicable Item 7. Identification and Classification of the Subsidiary Which Acquired the

View Full Filing

View this SC 13G/A filing on SEC EDGAR